We are live on ! Find out more

Gilead Sciences

GILD

Market cap $186B

150.11 USD

-0.78

0.52%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

150.50

+0.39

0.26%

1 day

-0.52%

5 days

4.06%

1 month

4.65%

3 months

21.29%

6 months

6.24%

Year to date

23.45%

1 year

32.12%

5 years

111.54%

10 years

90.04%

About: Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Employees: 17,000

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 59.3%

Neutral 34.6%

Negative 6.2%

Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF

MEXICO CITY--(BUSINESS WIRE)-- #Gilead--AIDS Healthcare Foundation (AHF), the world's largest HIV care provider, welcomes a new agreement between Gilead Sciences and the Pan American Health Organization (PAHO) that could expand access to lenacapavir for HIV prevention in 14 countries across Latin America. The agreement represents a positive step toward expanding access in the region and a victory for civil society. AHF was among the first organizations to mobilize around concerns that the initial Gilead-.

Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF

Zacks Investment Research

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Zacks Investment Research

Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America

GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.

Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreements cover 120 high-incidence countries (which are primarily low- and lower-middle-income) and will support manufacturing readiness, technology transfer and future supply planning while the.

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances

Gilead Sciences NASDAQ: GILD executives outlined plans to expand the company's HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O'Day describing the company as being at an “inflection point in value.”

Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances

Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean

U.S. drugmaker Gilead Sciences said on Tuesday it had reached an agreement with the Pan American Health Organization to widen access to its HIV prevention drug across Latin ‌America and the Caribbean, as the regions seek to curb new infections.

Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO Member States in Latin America and the Caribbean. Through PAHO's Regional Revolving Funds, the agreement establishes a coordinated regional pathway to expand access to long-acting HIV prevention and support country-led effor.

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

Zacks Investment Research

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.42, denoting a +1.88% move from the preceding trading day.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

See News Rankings

Price charts implemented using Lightweight Charts™